Nucleic Acids Res 1997,25(15):3124–30.PubMedCrossRef 15. Hori T, Guo F, Tanaka Y, Uesugi S: Design and properties of trans-acting HDV ribozymes with extended substrate recognition regions. Nucleic Acids Res Suppl 2001, (1):201–2. 16. Nishikawa F, Fauzi H, Nishikawa S: Detailed analysis of base preferences at the cleavage site of a transacting HDV ribozyme: a mutation that changes cleavage site specificity. Nucleic Acids Res 1997,25(8):1605–10.PubMedCrossRef 17. Corey DR: Telomerase inhibition, oligonucleotides, and clinical trials. Oncogene 2002,21(4):631–7. 10. Bisoffi M, Chakerian AE, Fore ML, Bryant JE, Hernandez JP, Moyzis RK, GSK1210151A research buy Griffith JK. Inhibition
of human telomerase by a retrovirus expressing {Selleck Anti-diabetic Compound Library|Selleck Antidiabetic Compound Library|Selleck Anti-diabetic Compound Library|Selleck Antidiabetic Compound Library|Selleckchem Anti-diabetic Compound Library|Selleckchem Antidiabetic Compound Library|Selleckchem Anti-diabetic Compound Library|Selleckchem Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|buy Anti-diabetic Compound Library|Anti-diabetic Compound Library ic50|Anti-diabetic Compound Library price|Anti-diabetic Compound Library cost|Anti-diabetic Compound Library solubility dmso|Anti-diabetic Compound Library purchase|Anti-diabetic Compound Library manufacturer|Anti-diabetic Compound Library research buy|Anti-diabetic Compound Library order|Anti-diabetic Compound Library mouse|Anti-diabetic Compound Library chemical structure|Anti-diabetic Compound Library mw|Anti-diabetic Compound Library molecular weight|Anti-diabetic Compound Library datasheet|Anti-diabetic Compound Library supplier|Anti-diabetic Compound Library in vitro|Anti-diabetic Compound Library cell line|Anti-diabetic Compound Library concentration|Anti-diabetic Compound Library nmr|Anti-diabetic Compound Library in vivo|Anti-diabetic Compound Library clinical trial|Anti-diabetic Compound Library cell assay|Anti-diabetic Compound Library screening|Anti-diabetic Compound Library high throughput|buy Antidiabetic Compound Library|Antidiabetic Compound Library ic50|Antidiabetic Compound Library price|Antidiabetic Compound Library cost|Antidiabetic Compound Library solubility dmso|Antidiabetic Compound Library purchase|Antidiabetic Compound Library manufacturer|Antidiabetic Compound Library research buy|Antidiabetic Compound Library order|Antidiabetic Compound Library chemical structure|Antidiabetic Compound Library datasheet|Antidiabetic Compound Library supplier|Antidiabetic Compound Library in vitro|Antidiabetic Compound Library cell line|Antidiabetic Compound Library concentration|Antidiabetic Compound Library clinical trial|Antidiabetic Compound Library cell assay|Antidiabetic Compound Library screening|Antidiabetic Compound Library high throughput|Anti-diabetic Compound high throughput screening| telomeric antisense RNA, Eur. J. Cancer. 1998, 34(8): 1242–9PubMedCrossRef 18. Naka K, Yokozaki H, Yasui W, Tahara H, Tahara
E, Tahara E: Effect of antisense human telomerase RNA transfection on the growth of human gastric cancer cell lines. Biochem Biophys Res Commun 1999, 255:753–58.PubMedCrossRef 19. Lue NF: A BIX 1294 mouse physical and functional constituent of telomerase anchor site. J Biol Chem 2005,280(28):26586–91.PubMedCrossRef 20. Romero DP, Blackburn EH: A conserved secondary structure for telomerase RNA. Cell 1991,67(2):343–53.PubMedCrossRef 21. Autexier C, Greider CW: Functional reconstitution of wild-type and mutant Tetrahymena telomerase. Genes Dev 1994,8(5):563–75.PubMedCrossRef 22. Fauzi H, Kawakami J, Nishikawa F, Nishikawa S: Analysis of the cleavage reaction of a trans-acting human hepatitis delta virus ribozyme. Nucleic Acids Res 1997,25(15):3124–30.PubMedCrossRef 23. Sirinart A, Perreault JP: Substrate specificity of delta
ribozyme cleavage. J Biol Chem 1998,273(21):13182–88.CrossRef 24. Tomlinson RL, Ziegler TD, Supakorndej T, Terns RM, Terns MP: Cell cycle-regulated trafficking of human telomerase to telomeres. Mol Biol Cell 2006,17(2):955–65.PubMedCrossRef 25. Bailin LIU, Yi QU, Shuqiu LIU, Xuesong Ouyang: Inhibition of telomerase in tumor cells by ribozyme targeting telomerase many RNA component SCIENCE IN CHINA (Series C). 2002,45(1):87–95. 26. Kruk PA, Orren DK, Bohr VA: Telomerase is elevated in early S phase in hamster cells, Biochem. Biophys Res Commun 1997, 233:712–22.CrossRef 27. Griffith JD, Comeau L, Rosenfield S, Stansel RM, Biachi A, Moss H, deLange T: Mammalian telomeres end in a large duplex loop. Cell 1999, 97:503–514.PubMedCrossRef 28. Wyllie FionaS, Jones ChristopherJ, Skinner JuliaW, Haughton MicheleF, Wallis Corrin, Wynford-Thomas David, Faragher RichardGA, Kipling David: Telomerase prevents the accelerated cell aging of Werner syndrome fibroblasts. Nat Genet 2000, 24:16–17.PubMedCrossRef 29. Ren JG, Xia HL, Tian YM, Just T, Cai GP, Dai YR: Expression of telomerase inhibits hydroxyl radical-induced apoptosis in normal telomerase negative human lung fibroblast. FEBS Lett 2001, 488:133–38.PubMedCrossRef 30.
